Study on Drug List and Accessibility of Rare Diseases Based on the China's Second List of Rare Diseases
10.12376/j.issn.2097-0501.2024.02.007
- VernacularTitle:基于《第二批罕见病目录》的罕见病药物目录和药物可及性研究
- Author:
Qingyang LIU
1
;
Xin LIU
;
Wei ZUO
;
Shaohong WANG
;
Bo ZHANG
;
Shuyang ZHANG
Author Information
1. 中国医学科学院北京协和医院药剂科,北京 100730
- Keywords:
rare diseases;
orphan drugs;
accessibility;
the China's Second List of Rare Diseases
- From:
JOURNAL OF RARE DISEASES
2024;3(2):195-201
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study aims to sort out the rare disease drugs in the China's Second List of Rare Diseases,to provide reference for the management of rare disease drug treatment.Methods Up to December 31,2023,based on the China's Second List of Rare Diseases,we sorted out the drugs approved in China with the drug label,or approved by the U.S.Food and Drug Administration(FDA)and the European Medicines Agency(EMA)for the treatment of the above diseases,and developed the second batch of rare dis-ease drug catalog in China.The accessibility,localization and coverage of the national medical insurance were also analyzed.Results From the point of view of diseases,a total of 37 diseases in the China's Second List of Rare Diseases have drug indications approved in China,and 10 diseases have drugs listed by the U.S.FDA/EMA and approved in China,but for off-label use.From the point of view of drugs,there are 55 drug indications ap-proved for the treatment of the China's Second List of Rare Diseases,and 22 drugs listed in the U.S.FDA/EMA and approved in the China,but for off-label use.Among the above-mentioned drugs with domestic approved rare disease indications or approved numbers,39 drugs have at least one domestic approval number for a dosage form,covering 30 rare diseases;37 drugs used for at least one rare disease are included in the national medical insur-ance catalog and are covered by reimbursement,covering 29 rare diseases.Conclusions The list of rare disease drugs in the China's Second List of Rare Diseases was established.The number of rare disease drugs and covered diseases approved by China and the U.S.FDA/EMA has increased,and the number of rare disease drugs and covered diseases that are localized and included in the medical insurance catalog has also continued to increase.
